These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1076 related items for PubMed ID: 27103020

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
    Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, Govindan R, Torigian DA, Karp JS, Yu JQ, Subramaniam RM, Halvorsen RA, Siegel BA, ACRIN 6678 Research team, MK-0646-008 Research team.
    J Nucl Med; 2015 Aug; 56(8):1137-43. PubMed ID: 25908829
    [Abstract] [Full Text] [Related]

  • 3. Variability and Repeatability of Quantitative Uptake Metrics in 18F-FDG PET/CT of Non-Small Cell Lung Cancer: Impact of Segmentation Method, Uptake Interval, and Reconstruction Protocol.
    Zhuang M, García DV, Kramer GM, Frings V, Smit EF, Dierckx R, Hoekstra OS, Boellaard R.
    J Nucl Med; 2019 May; 60(5):600-607. PubMed ID: 30389824
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
    Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, van Tinteren H, Boellaard R.
    J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 7. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 8. Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.
    Tixier F, Vriens D, Cheze-Le Rest C, Hatt M, Disselhorst JA, Oyen WJ, de Geus-Oei LF, Visser EP, Visvikis D.
    J Nucl Med; 2016 Jul; 57(7):1033-9. PubMed ID: 26966161
    [Abstract] [Full Text] [Related]

  • 9. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
    Liu H, Chen P, Wroblewski K, Hou P, Zhang CP, Jiang Y, Pu Y.
    Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P, Buchbender C, Köhler J, Nensa F, Beiderwellen K, Kühl H, Lanzman RS, Wittsack HJ, Gomez B, Gauler T, Schuler M, Forsting M, Bockisch A, Antoch G, Heusner TA.
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH, Chiu NT, Su WC, Guo HR, Lee BF.
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [Abstract] [Full Text] [Related]

  • 16. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancer.
    Hughes DJ, Josephides E, O'Shea R, Manickavasagar T, Horst C, Hunter S, Tanière P, Nonaka D, Van Hemelrijck M, Spicer J, Goh V, Bille A, Karapanagiotou E, Cook GJR.
    Eur Radiol; 2024 Sep; 34(9):5889-5902. PubMed ID: 38388716
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E, Turgut B, Cakmakcilar A, Erturk SA.
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. 18F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non-Small Cell Lung Cancer Patients: A Comparison of Assessment Methods.
    Fledelius J, Winther-Larsen A, Khalil AA, Bylov CM, Hjorthaug K, Bertelsen A, Frøkiær J, Meldgaard P.
    J Nucl Med; 2017 Dec; 58(12):1931-1937. PubMed ID: 28490472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.